How Is Unhealthy Lifestyle Fueling Human Insulin Demand?

0
353
Human-Insulin-HI-Market

Human Insulin (HI) Market

Human Insulin market :- In the recent times, there has been a steep rise in the sales of human insulin, primarily because of the growing incidence of diabetes all around the world. According to many surveys, the number of diabetic patients has grown from 108 million to 422 million from 1980 to 2014 and is predicted to increase to 592 million in 2035. This drastic growth in the population of diabetic people will massively push up the demand for human insulin in the future.

As per the International Diabetes Federation (IDF), 425 million people in the age bracket 20-79 years were diagnosed with diabetes in 2017 and this number is predicted to rise to 629 million in 2045. The growing prevalence of diabetes is not just restricted among the people living in the developed countries but also increasing rapidly among the populace of the developing nations. A key factor responsible for the growing prevalence of diabetes is the soaring geriatric population in many countries.

This is because with increasing age, the insulin-producing ability of the human body starts decreasing and as a result, the body loses its glucose synthesizing ability. According to findings of the Centers for Disease Control and Prevention (CDC), a national public health organization in the U.S., almost 25% of the people in the country in the age bracket 65 years and above have diabetes. This means that almost 12 million seniors in the U.S. are diabetic.

Apart from the surging geriatric population,

rapid technological advancements in insulin delivery devices are also positively impacting the global demand for human insulin. These factors are subsequently causing expansion of the global human insulin (HI) market. Between the HI delivery devices and drugs, the sales of the human insulin drugs were found to be significantly high in the years gone by, mainly because of the high incidence of diabetes and the presence of a large geriatric population in several countries.

Human insulin drugs are heavily required for the treatment and management of gestational diabetes and prediabetes and type I and type II diabetes. Amongst these diseases, the prevalence of type II diabetes was considerably high all over the globe during the past few years, as per the findings of P&S Intelligence, a market research firm based in India. As a result, human insulin products were heavily required for the treatment and management of this disease in the last few years.

Geographically

the human insulin market is predicted to exhibit explosive growth in the Asia-Pacific (APAC) region in the forthcoming years, on account of the rising incidence of diabetes, growing adoption of sedentary lifestyles, unhealthy eating habits of people, and increasing geriatric population in the regional countries such as India and China. Additionally, the human insulin device producing companies are rapidly expanding their operations in the APAC countries, which is, in turn, boosting the sales of human insulin in the region.

Therefore, it is quite clear that the demand for human insulin will rise enormously throughout the world in the forthcoming years, due to the rising incidence of diabetes, increasing geriatric population, and the development of technologically advanced human insulin delivery devices in several countries across the world.

In recent years,

diabetic patients have been showing a higher preference for the different variants

of the artificially produced hormone than delivery devices

due to the extensive research by pharmaceutical companies in drug discovery and development.

Essentially, devices, once bought, last years.

while the insulin vials and cartridges empty with regular use, prompting people to replenish their stock regularly.

Premixed,

long-acting,

and rapid-acting HI analogs and short-acting,

intermediate/rapid-acting, and premixed HI biologics are available for diabetes management.

These products are manufactured by Gulf Pharmaceutical Industries (Julphar),

Novo Nordisk A/S, Ypsomed AG, Wockhardt Ltd., Becton, Dickinson and Company, B. Braun Melsungen AG, Eli Lilly and Company, and Medtronic PLC. At present, these companies are focusing on product launches to offer new and improved HI variants and delivery devices to their existing and potential customers. For instance, Sanofi obtained the U.S. Food and Drug Administration (USFDA) approval for Admelog (insulin lispro injection) in December 2017. It is a rapid-acting insulin that enables people to manage their blood glucose levels at mealtime.

Globally, the North American region consumed the largest volume of HI and bought the highest number of delivery devices in the preceding years due to the escalating healthcare expenditure, burgeoning cases of diabetes, and increasing research and development (R&D) activities in the area of biosimilars. According to the National Diabetes Statistics Report 2020 by the Centers for Disease Control and Prevention (CDC), 34.2 million people in the U.S. suffer from diabetes. Out of this, nearly 26.9 million cases are diagnosed, whereas 7.3 million cases remain undiagnosed.

Whereas, the Asia-Pacific (APAC) human insulin market is expected to advance at the highest rate in the upcoming years. This will be due to the rising incidence of diabetes and soaring geriatric population in India and China.

For instance

the IDF forecasts that the number of diabetes patients in India within the age group of 20–79 years will surge from 77,005,600 in 2019

to 100,956,400 in 2030 and 134,239,300 in 2045.

Essentially, the shift toward an unhealthy lifestyle owing to the rapid urbanization

will propel the adoption of insulin and delivery devices in the region.

The market is registering growth due to the surging geriatric population

rising exposure of people toward key risk factors resulting to diabetes, and increase in the number of diabetic patients. A type of synthetic insulin which mimics the insulin in humans is referred to as human insulin. Human insulin is generally created by growing insulin protein in bacteria, E. coli.

When application is taken into consideration,

the human insulin market is categorized into gestational diabetes and prediabetes,

type I diabetes, and type II diabetes.

Out of these,

the type II diabetes category accounted for the largest revenue share of the market

during the historical period and is predicted to dominate the market during the forecast period as well.

Geographically, the market was dominated by North America during the historical period because of the rising healthcare expenditure, presence of key players, and growing R&D activities for the development of biosimilars in the region.

A major driving factor of the human insulin market is the rise in number of diabetic patients around the world.

The number of people suffering from diabetes rose from 108 million in 1980 to 422 million in 2014,

and this is number is further expected to reach 592 million by 2035.

This surge in the number of diabetic patients is not limited to just developed countries but developing countries as well.

According to the International Diabetes Federation,

the number of diabetic patients in India will reach up to 123 million by 2040.

Technological advancements in insulin delivery devices are also resulting in the growth of the human insulin market.

Insulin pumps,

pens,

inhalers,

have several advantages and aid in delivering the accurate dosage of insulin,

thereby making sure that the normal level of insulin in the body is maintained.

Using insulin pens for administering insulin is less time consuming than vials and syringes.

In addition to this, these pens are widely accepted and have minimum risk of inaccurate dosage.

A key trend being witnessed in the human insulin market:-

is the rising significance of home infusion therapy for the treatment of diabetes.

Because of the rising emphasis on cost-effectiveness in healthcare,

the preference for less costly sites such as homecare are gaining popularity over emergency departments or hospitals.

Home-based care provides greater convenience and flexibility.

Home infusion therapy is gaining acceptance among diabetic patients:-

due to the growing availability of advanced HI delivery devices, particularly insulin pumps.

Hence, the market is being driven by technological advancements and increase in the number of diabetic patients.

Therefore, the rising cases of diabetes owing to an unhealthy lifestyle will fuel the adoption of HI and delivery devices.

LEAVE A REPLY

Please enter your comment!
Please enter your name here